Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsFlagged areas: Earnings quality, Solvency & liquidity.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- 5 filing risk checks flagged
Flagged areas: Earnings quality, Solvency & liquidity.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +19.0% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Operating margin improved
Operating margin changed +5.6 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
- Free cash flow turned positive
Latest reported free cash flow was $2M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Earnings quality
- Solvency & liquidity
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Soft Tissue Repair Products$91.3M88.6%+20.0% yoy
- Bone Fusion Products$11.8M11.4%+11.6% yoy
Members sum to the consolidated $103M for this period.
- Soft Tissue Repair Products$24.9M89.7%+21.5% yoy
- Bone Fusion Products$2.86M10.3%-1.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 3,990 US-listed filers · 316 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $103M | 28thof 3,301 bottom third | 37thof 291 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 19.0% | 76thof 3,137 top third | 73rdof 277 top third |
Gross margin gross profit ÷ revenue | 92.7% | 98thof 1,603 top third | 98thof 212 top third |
Operating margin operating income ÷ revenue | 7.1% | 62ndof 2,819 middle third | 69thof 280 top third |
Net margin net income ÷ revenue | -36.4% | 21stof 3,263 bottom third | 30thof 290 bottom third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 2.1% | 40thof 2,679 middle third | 50thof 261 middle third |
Return on equity net income ÷ stockholders' equity (positive equity only) | -632.5% | 1stof 3,576 bottom third | 3rdof 291 bottom third |
Interest coverage operating income ÷ interest expense (interest expense > 0) | 1.1× | 49thof 819 middle third | 64thof 76 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 5.0% | 35thof 2,895 middle third | 41stof 272 middle third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | 4.3× | 31stof 1,546 bottom third | 25thof 116 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
Not available for SMTI yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..
Point-in-time ledger
Not available for SMTI yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..
Notes by disclosure type
Not available for SMTI yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.